WO2014147631A1 - Formulation comprising gefitinib as oral suspension - Google Patents
Formulation comprising gefitinib as oral suspension Download PDFInfo
- Publication number
- WO2014147631A1 WO2014147631A1 PCT/IN2013/000194 IN2013000194W WO2014147631A1 WO 2014147631 A1 WO2014147631 A1 WO 2014147631A1 IN 2013000194 W IN2013000194 W IN 2013000194W WO 2014147631 A1 WO2014147631 A1 WO 2014147631A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agents
- oral
- agent
- gefitinib
- suspension
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 239000005411 L01XE02 - Gefitinib Substances 0.000 title claims abstract description 41
- 229960002584 gefitinib Drugs 0.000 title claims abstract description 41
- 229940100692 oral suspension Drugs 0.000 title claims description 19
- 238000009472 formulation Methods 0.000 title abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000000725 suspension Substances 0.000 claims description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
- 239000000796 flavoring agent Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000003599 food sweetener Nutrition 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 12
- 239000000375 suspending agent Substances 0.000 claims description 12
- 239000003765 sweetening agent Substances 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- 239000007900 aqueous suspension Substances 0.000 claims description 11
- 239000006172 buffering agent Substances 0.000 claims description 11
- 239000003086 colorant Substances 0.000 claims description 11
- 239000000080 wetting agent Substances 0.000 claims description 11
- 239000002738 chelating agent Substances 0.000 claims description 10
- 235000013355 food flavoring agent Nutrition 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 7
- 239000005995 Aluminium silicate Substances 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000001692 EU approved anti-caking agent Substances 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- 235000012211 aluminium silicate Nutrition 0.000 claims description 6
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims description 6
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 229960003943 hypromellose Drugs 0.000 claims description 5
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical group [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 5
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 5
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229960002216 methylparaben Drugs 0.000 claims description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229960003415 propylparaben Drugs 0.000 claims description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 4
- 235000002639 sodium chloride Nutrition 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical group O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- 235000019204 saccharin Nutrition 0.000 claims description 3
- 229940081974 saccharin Drugs 0.000 claims description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 235000001055 magnesium Nutrition 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 10
- 239000002552 dosage form Substances 0.000 abstract description 9
- 201000010536 head and neck cancer Diseases 0.000 abstract description 7
- 208000014829 head and neck neoplasm Diseases 0.000 abstract description 7
- 230000001394 metastastic effect Effects 0.000 abstract description 7
- 206010061289 metastatic neoplasm Diseases 0.000 abstract description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 238000009097 single-agent therapy Methods 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 235000019629 palatability Nutrition 0.000 abstract 1
- 239000007971 pharmaceutical suspension Substances 0.000 abstract 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
- 235000019634 flavors Nutrition 0.000 description 11
- 239000003826 tablet Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 235000005979 Citrus limon Nutrition 0.000 description 6
- 244000131522 Citrus pyriformis Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- -1 wettm"g~ageTTts Substances 0.000 description 6
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229960002303 citric acid monohydrate Drugs 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
- 229940068968 polysorbate 80 Drugs 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 5
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 5
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 5
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YSVBPNGJESBVRM-ZPZFBZIMSA-L Carmoisine Chemical compound [Na+].[Na+].C1=CC=C2C(/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)O)=CC=C(S([O-])(=O)=O)C2=C1 YSVBPNGJESBVRM-ZPZFBZIMSA-L 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000004176 azorubin Substances 0.000 description 3
- 235000012733 azorubine Nutrition 0.000 description 3
- 229940031019 carmoisine Drugs 0.000 description 3
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940051147 fd&c yellow no. 6 Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229940051201 quinoline yellow Drugs 0.000 description 3
- 235000012752 quinoline yellow Nutrition 0.000 description 3
- FZUOVNMHEAPVBW-UHFFFAOYSA-L quinoline yellow ws Chemical compound [Na+].[Na+].O=C1C2=CC=CC=C2C(=O)C1C1=NC2=C(S([O-])(=O)=O)C=C(S(=O)(=O)[O-])C=C2C=C1 FZUOVNMHEAPVBW-UHFFFAOYSA-L 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- ZDTNHRWWURISAA-UHFFFAOYSA-N 4',5'-dibromo-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C(Br)=C1OC1=C(Br)C(O)=CC=C21 ZDTNHRWWURISAA-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- 239000001329 FEMA 3811 Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000010634 bubble gum Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000010632 citronella oil Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 229940075482 d & c green 5 Drugs 0.000 description 1
- 229940090962 d&c orange no. 5 Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- FPAYXBWMYIMERV-UHFFFAOYSA-L disodium;5-methyl-2-[[4-(4-methyl-2-sulfonatoanilino)-9,10-dioxoanthracen-1-yl]amino]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1S([O-])(=O)=O FPAYXBWMYIMERV-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 101150028517 hlb gene Proteins 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960003476 methylparaben sodium Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000000978 natural dye Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 1
- 235000010434 neohesperidine DC Nutrition 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 239000000574 octyl gallate Substances 0.000 description 1
- 235000010387 octyl gallate Nutrition 0.000 description 1
- NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000001631 piper nigrum l. fruit oil black Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- HEKURBKACCBNEJ-UHFFFAOYSA-M potassium;1,1-dioxo-1,2-benzothiazol-2-id-3-one Chemical compound [K+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 HEKURBKACCBNEJ-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005359 propylparaben sodium Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- LLELVHKMCSBMCX-UHFFFAOYSA-M sodium 1-[(4-chloro-5-methyl-2-sulfophenyl)diazenyl]naphthalen-2-olate Chemical compound [Na+].Cc1cc(N=Nc2c(O)ccc3ccccc23)c(cc1Cl)S([O-])(=O)=O LLELVHKMCSBMCX-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000979 synthetic dye Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Definitions
- the present invention relates to pharmaceutical compositions of gefitinib and process of preparation thereof.
- Gefitinib is an antineoplastic agent and it is chemically designated as 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-mo holi ) propoxy] with molecular formula C 22 H2 4 C1FN 4 0 3 and currently indicated for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies.
- Gefitinib is a useful addition to treatment of patientsj ⁇ ith.locaU-v-ad-vaneed-head-and'n ' euk cancer.
- Gefitinib is commercially available as film coated tablets of 250 mg strength under the trade name of Iressa ® manufactured by Astrazeneca.
- Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK).
- EGFR is expressed on the cell surface of many normal cells and cancer cells.
- Gefitinib is slowly absorbed after oral administration with peak plasma levels occurring 3-7 hours after dosing. It was also reported that mean oral bioavailability is 60%. Biotransformation of gefitinib is via hepatic metabolism and cytochrome P450 enzymes (especially CYP3A4). .
- Gefitinib is extensively distributed throughout the body with a mean steady state volume of distribution of 1400 L following intravenous administration. In vitro binding of gefitinib to human plasma proteins (serum albumin and a 1 -acid glycoprotein) is 90% and is independent of drug concentrations.
- Gefitinib is cleared primarily by the liver, with total plasma clearance and elimination half-life values of 595 mL/min and 48 hours, respectively, after intravenous administration. Excretion is predominantly via the feces (86%), with renal elimination of drug and metabolites accounting for less than 4% of the administered dose.
- U.S. Patent nos. 5457105, 5616582, 5770599 discloses synthesis of gefitinib and pharmaceut-iGall-y-aeeeptable-saltsT ⁇ he ingredients for formulation of conventional tablets detailed in this prior art comprise active ingredient, lactose, croscarmellose sodium, maize starch, polyvinyl pyrrolidone, magnesium stearate.
- EP 0823900 Bl and WO 96/33980 disclose the same.
- WO 2005/070909, WO 2010/076810 and U.S. Patent application no. 20100137586 discloses process for preparation of gefitinib.
- WO 2006/090413 describes a stable novel crystalline form of gefitinib and a process for the preparation of the same which is useful in the treatment of a variety of solid tumors.
- the prior art discloses methods and pharmaceutical composition of a therapeutic agent which enhances sensitivity of a cancer to a molecular target drug in U.S. Patent application no. 20120064090, U.S. Patent no. 8017321 corresponding PCT application no. PCT/US2005/002325.
- U.S. Patent application no. like 201 10294686, 20070270505 also disclose the same.
- U.S. Patent application no. 20090098138 corresponding PCT application no. PCT/US07/66857 and U.S. Patent application no. 20100173285 discloses a method of detecting the expression of a protein from circulating cancer cells and EGFR mutations to determine patient responsiveness to gefitinib administration.
- U.S. Patent application no. 20090185999 and 20090186892 discloses quinazoline derivatives for treating lung cancers.
- Gefitinib is presently available as tablet dosage form in market. None of the above said prior arts discloses and/or envisages an oral suspension. Hence, the development of an oral suspension alleviates problems associated with swallowing tablets in head and neck cancer patients.
- the oral suspension dosage form can also be a viable alternative for geriatric patients who unable to or prefer not to swallow a solid dosage form since it o-ffer-s-impFOved-pat-ient-complianc ⁇ n n Eable with good organoleptic properties.
- gefitinib is having all the above favorable features suitable to formulate an oral suspension, the work on present invention was taken up.
- the present invention relates to design and development of an oral suspension containing gefitinib and a process for its preparation, indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer or unresectable head and neck cancer.
- the main objective of the present invention is to design and develop an oral suspension containing gefitinib for monotherapy treatment for locally advanced or metastatic non-small cell lung cancer or unresectable head and neck cancer.
- Another objective of this invention is to provide a dosage form ensuring adequate therapeutic levels of drug concentration.
- Another objective of this invention is to provide a desirable oral formulation for the — treatment-of-elderly ⁇ tteTiislto swallow easily.
- Yet another objective of the present invention is to provide simple process for the preparation of a stable aqueous formulation of gefitinib.
- Yet another objective of the present invention enhances patient compliance.
- further objective of this invention is to provide the pharmaceutical composition of an oral suspension to ensure adequate therapeutic levels for the therapy against aforementioned diseases. Accordingly, further objective of this invention is to meet the particular needs of patients who find difficulty in swallowing solid oral dosage forms.
- the objective of the present invention is to develop a process for preparing the oral suspension comprising active ingredient, one or more of a vehicle, suspending agent, preservatives, wetting agents, sweetening agents, buffering agents, anticaking agents, chelating agent, antioxidants, flavoring agent, coloring agents and the like.
- the main embodiment of the present invention is to design and develop a stable aqueous oral formulation that can be swallowed easily and comprising gefitinib, a process for its preparation, wherein the said formulation has pH in the range of about 2.5 to 5.5 for the monotherapy treatment of locally advanced or metastatic non-small cell lung cancer or unresectable head and neck cancer.
- An aqueous suspension for oral administration in humans comprising of therapeutically effective amount of gefitinib, one or more of a vehicle, suspending agent, preservatives, wettm " g ⁇ ageTTts, sweetening agents, buffering agents, anticaking agents, chelating agent, antioxidants, flavoring agent, coloring agents and the like intended to treat metastatic non-small cell lung cancer or unresectable head and neck cancer.
- the formulation of the present invention comprises wherein the oral suspension contains a therapeutically effective pharmaceutical ingredient, gefitinib used in the range of about 0.1% to about 20%, by weight by volume of the total suspension.
- compositions of the present invention include a vehicle which is pharmaceutically acceptable serves as the external phase of the suspensions.
- a preferred vehicle of the present invention may include water, glycerin, propylene glycol and mixtures thereof.
- other vehicles may include but not restricted to, sorbitol solution, polyethylene glycol and the like.
- the formulation of the present invention may include an appropriate amount of suspending agents that can add a desired viscosity and flow to a formulation or effective to stabilize the pharmaceutically active agent within the aqueous composition.
- suspending agents for example, in a suspension a viscosity enhancer will help to keep the active ingredient suspended to allow accurate dosing.
- a preferred suspending agent of the present invention may include hypromellose, polyvinylpyrrolidone, magnesium aluminium silicate and xanthan gum.
- suspending agents may include but not restricted to, carbomer, hydrocolloid gums like guar gum, gum tragacanth and cellulose derivatives for example methyl-, ethyl- and propyl celluloses; hydroxyalkyl-celluloses, hydroxyl propyl celluloses, hydroxylpropylalkyl celluloses, sodium carboxy methyl cellulose, micro
- resins polyethylene glycol, polyethylene oxide, sodium alginate and the like.
- compositions of the present invention may include an appropriate amount of preservatives to prevent growth of micro organisms.
- a preferred anti microbial agents of the present invention is benzyl alcohol, methyl and propyl parabens.
- preservatives may include but not restricted to, butyl paraben, ethyl paraben, sorbic acid, potassium sorbate, benzalkonium chloride, benzoic acid and its derivatives such as sodium benzoate and the like.
- compositions of the present invention include wetting agents to increase suspendability of hydrophobic drugs in aqueous media by reducing interfacial tension between drug particles and the suspension vehicle, thereby allowing penetration of suspension vehicle into drug aggregates and/or drug particle pores.
- a preferred wetting agent of the present invention may include sodium lauryl sulphate and polyoxyethylene derivatives of sorbitan esters (polysorbate 20, 40, 60 and 80).
- wetting agents may include but are not restricted to, poloxamers (ethylene oxide propylene oxide block copolymers) of different HLBs, polyethylene glycols and the like.
- compositions of the present invention may include an appropriate amount of sweetening agents used for better patient acceptability of the dosage form and also enhances the flavor system.
- a preferred sweetening agent of the present invention may include sucralose, sorbitol solution and saccharin.
- other sweetening agents may include but not restricted to, natural sweeteners such as sugars eg.
- fructose sucrose, glucose, sugar alcohols such as mannitol or mixtures thereof and artificial sweeteners such as sodium saccharin, potassium saccharin, sodium cyclamate, aspartame, thaumatin, acesulfame potassium, altitame, neotame, xylose, ribose, mannose, galactose, neohesperidin dihydrochalcone and the like.
- artificial sweeteners such as sodium saccharin, potassium saccharin, sodium cyclamate, aspartame, thaumatin, acesulfame potassium, altitame, neotame, xylose, ribose, mannose, galactose, neohesperidin dihydrochalcone and the like.
- the sweetening agent used either single or in combinations in the range of about 0.01% to about 40%, by weight by volume of the total suspension.
- compositions of the present invention may include an appropriate amount of buffering agents to adjust / maintain the pH of suspension.
- the suspension according to present invention has a pH of about 2.5 to 5.5.
- a preferred buffering agent of the present invention is selected from citric acid, sodium citrate or mixture thereof.
- optionally other agents include but not restricted to, phosphoric acid, succinic acid, tartaric, lactic acid, acetic acid and salts thereof, sodium hydroxide, sodium phosphate, sodium chloride, disodium hydrogen phosphate, sodium hydrogen carbonate, monosodium phosphate, monopotassium phosphate, potassium citrate and mixtures thereof.
- the buffering agents used either single or in combinations to adjust pH (2.5 to 5.5) in the range of about 0.01% to about 10%, by weight by volume of the total suspension.
- compositions of the present invention include anticaking agent to prevent the formation of cake in formulation of suspension.
- a pr.efexre.d_anticak-ing— g&nt— of— the— resent— invention may include colloidal silicon dioxide.
- anticaking agent may include but not restricted to, calcium phosphate tribasic, magnesium oxide, magnesium silicate, calcium silicate and the like.
- compositions of the present invention may include an appropriate amount of chelating agents in a suitable concentration range to stabilize the product during storage.
- a preferred chelating agent of the present invention may include disodium edetate and the like.
- other agents may include but not restricted to, edetic acid, tartaric acid, malic acid, citric acid and salts thereof.
- compositions of the present invention may include an appropriate amount of antioxidants in a suitable concentration range to prevent oxidation.
- a preferred antioxidant of the present invention may include sodium metabisulfite.
- other agents include but not restricted to, ascorbic acid, sodium sulfite, sodium bisulfate, sodium thiosulfate, sodium ascorbate, sodium formaldehydesulfoxylate, malic acid, alkyl gallates like propyl gallate, lauryl gallate, or octyl gallate and the like.
- the antioxidant used either single or in combinations in the range of about 0.01% to about 5%, by weight by volume of the total suspension.
- compositions of the present invention comprise pharmaceutically acceptable aqueous or oil based flavoring agents to impart a pleasant flavor and often odor to a pharmaceutical preparation and can enhance patient— compliance— b-v— making— t-he-e&mpositrorr ⁇ m Te palatable.
- a preferred flavoring agent of the present invention is lemon flavor.
- non-limiting examples of flavoring agents may include but not restricted to orange sweet oil, spearmint oil, citronella oil, black pepper oil, pine apple, cherry, vanilla, honey, lemon, strawberry, raspberry, black current, caramel chocolate, mint cool, fantasy flavor, bubble gum, citrus, lemon, lime, apple, apricot, peppermint, spearmint peach, pear, plum flavor and the like.
- the flavoring agent used either single or in combinations in the range of about 0.05% to about 10%), by weight by volume of the total suspension.
- compositions of the present invention may include an appropriate amount of pharmaceutically acceptable aqueous or oil based colors to provide a product with a more aesthetic and/or distinctive appearance.
- a preferred coloring agent of the present invention is D&C Yellow No.10.
- other agents includes natural or synthetic dyes but not restricted to carmoisine, FD&C Yellow No.5, FD&C Yellow No.6, FD&C Red No.3, FD&C Red No.20, FD&C Blue No.2, D&C Green No.5, , D&C Yellow No.7, D&C Orange No.5, D&C Red No.8, caramel and the like.
- the coloring agents used either single or in combinations in the range of about 0.001 % to about 2%, by weight by volume of the total suspension.
- An aqueous suspension may further include one or more pharmaceutically acceptable additives.
- the particle size of the present invention is measured using light scattering technique (Malvern Sizer).
- the fine particle size contributes to homogeneity on prolonged storage,
- the average particle size of the gefitinib in the present invention is less than about 50 ⁇ .
- the present invention containing pharmaceutical active agent present at concentrations of 50 mg per mL, 25 mg per mL may be prepared with the above mentioned excipients using different proportions.
- An aqueous suspension of the present invention is easily administrable for geriatric patients and thus patient compliance can be achieved.
- a pharmaceutical composition of the present invention may be used in the treatment of the human or animal body by therapy.
- a process for the preparation of an oral suspension comprising mixing therapeutically effective amount of Gefitinib with vehicle containing preservatives followed by addition of one or more suspending agent dispersed in water, wetting agents, sweetening agents, buffering agents, anticaking agents, chelating agent, antioxidants, flavoring agent and coloring agents where in the said suspension has a pH from 2.5 to 5.5.
- the formulations of the present invention were found to be stable throughout the stability testing storage period.
- Figure 1 shows the bioavailability study of the formulation of the present invention and tablet dosage form of gefitinib.
- the details of the process of the invention are provided in the examples given below which is provided by way of illustration only and therefore should not be construed to limit the scope of the invention.
- the preparation of the present invention that can be administered by the oral route is carried out according to the following process: EXAMPLES
- the present invention provides a process for preparation of a composition, which comprises intimately mixing gefitinib with a vehicle containing preservatives followed by addition of one or more suspending agent dispersed in water, wetting agents, sweetening agents, buffering agents, anticaking agents, chelating agent, antioxidants, flavoring agent, coloring agents and mixed properly through high speed homogenizer until a homogeneous suspension is obtained or as mentioned under individual examples.
- compositions of Example 1 to 20 contains the
- Example 1 Example 2 Example 3 Example 4
- Sorbitol solution (70% w/v) 20.00 20.00 20.00 20.00 20.00
- Citric acid monohydrate 0.20 0.20 0.20 0.20 0.20 0.20
- Purified water (qs to 100% w/v) as needed as needed as needed as needed as needed as needed as needed as needed.
- the processing steps involved in manufacturing an oral suspension given in example 1 to 4 were given below.
- step (1) Preservative was added to vehicle under stirring followed by addition of wetting agent and added to step (1) 3. pH of the suspension was adjusted to a desired value as needed by adding buffering agents and added to step (2).
- Sorbitol solution (70% w/v) 0.00 0.00 0.00 20.00
- Methyl paraben sodium 0.00 0.00 0.18 0.18
- Citric acid monohydrate 0.20 0.20 0.00 0.00
- Example 9 Example 10 Example 1 1 Example 12
- Sorbitol solution (70% w/v) 0.00 . 20.00 20.00 20.00
- Polysorbate 80 0.00 0.50 0.50 0.25
- Methyl paraben 0.18 0.00 0.00 0.00
- Citric acid monohydrate 0.20 0.20 0.20 0.20 0.20 0.20
- Purified water (qs to 100% w/v) as needed as needed as needed as needed as needed as needed as needed
- Sorbitol solution (70% w/v) 20.00 20.00 20.00 20.00 20.00
- Citric acid monohydrate 0.20 0.20 0.20 0.20 0.20 0.20
- Sorbitol solution (70% w/v) 20.00 20.00 20.00 20.00 20.00
- Citric acid monohydrate 0.20 0.20 0.20 0.20 0.20 0.20
- Purified water (qs to 100% w/v) as needed as needed as needed as needed as needed as needed as needed
- the plasma kinetics of the oral suspension as described in above mentioned examples have been compared with those of the gefitinib tablets in a comparative study.
- This comparative study was carried out with wistar albino rats; weighing 150-280 grams which were divided into different sets of study (one male and one female in each set) and fasted overnight prior to dosing, but were permitted water ad libitum. Both formulations were administered at the dose of 20 mg/kg body weight.
- Blood samples were collected by puncturing retero-orbital sinus of the anaesthetized rats (with anesthetic light isoflurane) at different intervals post administration. Blood collection was done in prefilled heparin centrifugation tubes.
- the blood samples collected were subjected for the subsequent centrifugation and followed by analytical procedure with the use of LCMS technique.
- the areas under the blood drug concentration versus time curves were calculated by the trapezoidal rule. The analysis was done with respect to AUC (area under curve) and C ma x (maximum concentration).
- compositions in accordance with the present invention exhibit adequate bioavailability (AUC and C max ) in comparison with the commercial tablet dosage form.
- the aforementioned table gives an account of the bioavailability (AUC, C max ) of the Gefitinib tablet dosage form and formulation in the present invention.
- ADVANTAGES OF THE INVENTION a) Oral suspension of an aniloquinazoline derivative for example gefitnib is prepared which is used as EGFR tyrosine kinase inhibitor for the monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer or unresectable head and neck cancer.
- Gefitinib oral suspension can be a viable alternative to patients who find it difficult to swallow solid dosage forms.
- the advantage also lies in the attainment of adequate therapeutic levels of drug concentration in comparison with the commercial tablet dosage form.
- the advantage further encompasses the stability aspects and the formulation is found to be stable throughout the period of the stability study.
Abstract
A pharmaceutical suspension suitable for oral administration containing an effective amount of gefitinib to improve palatability, ensuring adequate therapeutic levels of drug concentration, in comparison to the commercial tablet dosage form and thus patient compliance can be achieved. The invention also relates to a process for the preparation of stable aqueous oral formulation that can be swallowed easily and comprising active ingredient in an effective concentration for the better therapy especially for the monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer or unresectable head and neck cancer.
Description
FORMULATION COMPRISING GEFITINIB AS ORAL SUSPENSION
FIELD OF THE INVENTION
The present invention relates to pharmaceutical compositions of gefitinib and process of preparation thereof.
BACKGROUND OF THE INVENTION
Gefitinib is an antineoplastic agent and it is chemically designated as 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-mo holi ) propoxy] with molecular formula C22H24C1FN403 and currently indicated for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies. Gefitinib is a useful addition to treatment of patientsj^ith.locaU-v-ad-vaneed-head-and'n'euk cancer.
Gefitinib is commercially available as film coated tablets of 250 mg strength under the trade name of Iressa® manufactured by Astrazeneca.
Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.
Gefitinib is slowly absorbed after oral administration with peak plasma levels occurring 3-7 hours after dosing. It was also reported that mean oral bioavailability is 60%. Biotransformation of gefitinib is via hepatic metabolism and cytochrome P450 enzymes (especially CYP3A4). .
Gefitinib is extensively distributed throughout the body with a mean steady state volume of distribution of 1400 L following intravenous administration. In vitro binding of
gefitinib to human plasma proteins (serum albumin and a 1 -acid glycoprotein) is 90% and is independent of drug concentrations.
Gefitinib is cleared primarily by the liver, with total plasma clearance and elimination half-life values of 595 mL/min and 48 hours, respectively, after intravenous administration. Excretion is predominantly via the feces (86%), with renal elimination of drug and metabolites accounting for less than 4% of the administered dose.
Daily oral administration of gefitinib to cancer patients resulted in a 2-fold accumulation compared to single dose administration. Steady state plasma concentrations are achieved within 10 days.
U.S. Patent nos. 5457105, 5616582, 5770599 discloses synthesis of gefitinib and pharmaceut-iGall-y-aeeeptable-saltsT^he ingredients for formulation of conventional tablets detailed in this prior art comprise active ingredient, lactose, croscarmellose sodium, maize starch, polyvinyl pyrrolidone, magnesium stearate. In addition, EP 0823900 Bl and WO 96/33980 disclose the same.
WO 2005/070909, WO 2010/076810 and U.S. Patent application no. 20100137586 discloses process for preparation of gefitinib.
WO 2006/090413 describes a stable novel crystalline form of gefitinib and a process for the preparation of the same which is useful in the treatment of a variety of solid tumors. The prior art discloses methods and pharmaceutical composition of a therapeutic agent which enhances sensitivity of a cancer to a molecular target drug in U.S. Patent application no. 20120064090, U.S. Patent no. 8017321 corresponding PCT application no. PCT/US2005/002325. In addition U.S. Patent application no. like 201 10294686, 20070270505 also disclose the same.
U.S. Patent application no. 20090098138 corresponding PCT application no. PCT/US07/66857 and U.S. Patent application no. 20100173285 discloses a method of detecting the expression of a protein from circulating cancer cells and EGFR mutations to determine patient responsiveness to gefitinib administration.
U.S. Patent application no. 20090185999 and 20090186892 discloses quinazoline derivatives for treating lung cancers.
Gefitinib is presently available as tablet dosage form in market. None of the above said prior arts discloses and/or envisages an oral suspension. Hence, the development of an oral suspension alleviates problems associated with swallowing tablets in head and neck cancer patients. The oral suspension dosage form can also be a viable alternative for geriatric patients who unable to or prefer not to swallow a solid dosage form since it o-ffer-s-impFOved-pat-ient-complianc^n n Eable with good organoleptic properties.
Since gefitinib is having all the above favorable features suitable to formulate an oral suspension, the work on present invention was taken up.
The present invention, relates to design and development of an oral suspension containing gefitinib and a process for its preparation, indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer or unresectable head and neck cancer.
There is a need to work on formulations and process thereof, - which proves better therapeutic efficacy, ease of oral administration and to be economical for large-scale production.
OBJECTIVES OF THE INVENTION
Accordingly, the main objective of the present invention is to design and develop an oral suspension containing gefitinib for monotherapy treatment for locally advanced or metastatic non-small cell lung cancer or unresectable head and neck cancer.
Another objective of this invention is to provide a dosage form ensuring adequate therapeutic levels of drug concentration.
Another objective of the present invention is to provide a stable oral liquid composition. Another objective of the present invention is to provide an oral liquid formulation with a palatable taste.
Another objective of this invention is to provide a desirable oral formulation for the — treatment-of-elderly^tteTiislto swallow easily.
Yet another objective of the present invention is to provide simple process for the preparation of a stable aqueous formulation of gefitinib.
Yet another objective of the present invention enhances patient compliance.
Accordingly, further objective of this invention is to provide the pharmaceutical composition of an oral suspension to ensure adequate therapeutic levels for the therapy against aforementioned diseases. Accordingly, further objective of this invention is to meet the particular needs of patients who find difficulty in swallowing solid oral dosage forms.
More especially, the objective of the present invention is to develop a process for preparing the oral suspension comprising active ingredient, one or more of a vehicle, suspending agent, preservatives, wetting agents, sweetening agents, buffering agents,
anticaking agents, chelating agent, antioxidants, flavoring agent, coloring agents and the like.
STATEMENT OF INVENTION
Accordingly, the main embodiment of the present invention is to design and develop a stable aqueous oral formulation that can be swallowed easily and comprising gefitinib, a process for its preparation, wherein the said formulation has pH in the range of about 2.5 to 5.5 for the monotherapy treatment of locally advanced or metastatic non-small cell lung cancer or unresectable head and neck cancer.
DETAILED DESCRIPTION OF THE INVENTION
An aqueous suspension for oral administration in humans comprising of therapeutically effective amount of gefitinib, one or more of a vehicle, suspending agent, preservatives, wettm"g~ageTTts, sweetening agents, buffering agents, anticaking agents, chelating agent, antioxidants, flavoring agent, coloring agents and the like intended to treat metastatic non-small cell lung cancer or unresectable head and neck cancer.
The formulation of the present invention comprises wherein the oral suspension contains a therapeutically effective pharmaceutical ingredient, gefitinib used in the range of about 0.1% to about 20%, by weight by volume of the total suspension.
Compositions of the present invention include a vehicle which is pharmaceutically acceptable serves as the external phase of the suspensions. A preferred vehicle of the present invention may include water, glycerin, propylene glycol and mixtures thereof.
Optionally other vehicles may include but not restricted to, sorbitol solution, polyethylene glycol and the like.
The vehicle used either single or in combinations in the range of about 1 % to about 90%, by weight by volume of the total suspension.
The formulation of the present invention may include an appropriate amount of suspending agents that can add a desired viscosity and flow to a formulation or effective to stabilize the pharmaceutically active agent within the aqueous composition. For example, in a suspension a viscosity enhancer will help to keep the active ingredient suspended to allow accurate dosing. A preferred suspending agent of the present invention may include hypromellose, polyvinylpyrrolidone, magnesium aluminium silicate and xanthan gum. Optionally other suspending agents may include but not restricted to, carbomer, hydrocolloid gums like guar gum, gum tragacanth and cellulose derivatives for example methyl-, ethyl- and propyl celluloses; hydroxyalkyl-celluloses, hydroxyl propyl celluloses, hydroxylpropylalkyl celluloses, sodium carboxy methyl cellulose, micro
resins, polyethylene glycol, polyethylene oxide, sodium alginate and the like.
The suspending agents used either single or in combinations in the range of about 0.05% to about 20%, by weight by volume of the total suspension. Compositions of the present invention may include an appropriate amount of preservatives to prevent growth of micro organisms. A preferred anti microbial agents of the present invention is benzyl alcohol, methyl and propyl parabens.
Optionally other preservatives may include but not restricted to, butyl paraben, ethyl paraben, sorbic acid, potassium sorbate, benzalkonium chloride, benzoic acid and its derivatives such as sodium benzoate and the like.
The preservatives used either single or in combinations in the range of about 0.005% to about 5%, by weight by volume of the total suspension.
Compositions of the present invention include wetting agents to increase suspendability of hydrophobic drugs in aqueous media by reducing interfacial tension between drug particles and the suspension vehicle, thereby allowing penetration of suspension vehicle into drug aggregates and/or drug particle pores. A preferred wetting agent of the present invention may include sodium lauryl sulphate and polyoxyethylene derivatives of sorbitan esters (polysorbate 20, 40, 60 and 80).
Optionally other wetting agents may include but are not restricted to, poloxamers (ethylene oxide propylene oxide block copolymers) of different HLBs, polyethylene glycols and the like.
The wetting agents used either single or in combinations in the range of about 0.05% to about 20%, by weight by volume of the total suspension. Compositions of the present invention may include an appropriate amount of sweetening agents used for better patient acceptability of the dosage form and also enhances the flavor system. A preferred sweetening agent of the present invention may include sucralose, sorbitol solution and saccharin. Optionally other sweetening agents may include but not restricted to, natural sweeteners such as sugars eg. fructose, sucrose, glucose, sugar alcohols such as mannitol or mixtures thereof and artificial sweeteners such as sodium saccharin, potassium saccharin, sodium cyclamate, aspartame, thaumatin, acesulfame potassium, altitame, neotame, xylose, ribose, mannose, galactose, neohesperidin dihydrochalcone and the like.
The sweetening agent used either single or in combinations in the range of about 0.01% to about 40%, by weight by volume of the total suspension.
Compositions of the present invention may include an appropriate amount of buffering agents to adjust / maintain the pH of suspension. The suspension according to present
invention has a pH of about 2.5 to 5.5. A preferred buffering agent of the present invention is selected from citric acid, sodium citrate or mixture thereof.
Optionally other agents include but not restricted to, phosphoric acid, succinic acid, tartaric, lactic acid, acetic acid and salts thereof, sodium hydroxide, sodium phosphate, sodium chloride, disodium hydrogen phosphate, sodium hydrogen carbonate, monosodium phosphate, monopotassium phosphate, potassium citrate and mixtures thereof. The buffering agents used either single or in combinations to adjust pH (2.5 to 5.5) in the range of about 0.01% to about 10%, by weight by volume of the total suspension.
Compositions of the present invention include anticaking agent to prevent the formation of cake in formulation of suspension. A pr.efexre.d_anticak-ing— g&nt— of— the— resent— invention may include colloidal silicon dioxide.
Optionally other anticaking agent may include but not restricted to, calcium phosphate tribasic, magnesium oxide, magnesium silicate, calcium silicate and the like. The anticaking agent used either single or in combinations in the range of about 0.01% to about 10%, by weight by volume of the total suspension.
Compositions of the present invention may include an appropriate amount of chelating agents in a suitable concentration range to stabilize the product during storage. A preferred chelating agent of the present invention may include disodium edetate and the like. Optionally other agents may include but not restricted to, edetic acid, tartaric acid, malic acid, citric acid and salts thereof.
The chelating agent used either single or in combinations in the range of about 0.01% to about 5%, by weight by volume of the total suspension.
Compositions of the present invention may include an appropriate amount of antioxidants in a suitable concentration range to prevent oxidation. A preferred antioxidant of the present invention may include sodium metabisulfite. Optionally other agents include but not restricted to, ascorbic acid, sodium sulfite, sodium bisulfate, sodium thiosulfate, sodium ascorbate, sodium formaldehydesulfoxylate, malic acid, alkyl gallates like propyl gallate, lauryl gallate, or octyl gallate and the like.
The antioxidant used either single or in combinations in the range of about 0.01% to about 5%, by weight by volume of the total suspension.
Compositions of the present invention comprise pharmaceutically acceptable aqueous or oil based flavoring agents to impart a pleasant flavor and often odor to a pharmaceutical preparation and can enhance patient— compliance— b-v— making— t-he-e&mpositrorr~m Te palatable. A preferred flavoring agent of the present invention is lemon flavor.
Optionally, non-limiting examples of flavoring agents may include but not restricted to orange sweet oil, spearmint oil, citronella oil, black pepper oil, pine apple, cherry, vanilla, honey, lemon, strawberry, raspberry, black current, caramel chocolate, mint cool, fantasy flavor, bubble gum, citrus, lemon, lime, apple, apricot, peppermint, spearmint peach, pear, plum flavor and the like.
The flavoring agent used either single or in combinations in the range of about 0.05% to about 10%), by weight by volume of the total suspension.
Compositions of the present invention may include an appropriate amount of pharmaceutically acceptable aqueous or oil based colors to provide a product with a more aesthetic and/or distinctive appearance. A preferred coloring agent of the present invention is D&C Yellow No.10.
Optionally other agents includes natural or synthetic dyes but not restricted to carmoisine, FD&C Yellow No.5, FD&C Yellow No.6, FD&C Red No.3, FD&C Red No.20, FD&C Blue No.2, D&C Green No.5, , D&C Yellow No.7, D&C Orange No.5, D&C Red No.8, caramel and the like.
The coloring agents used either single or in combinations in the range of about 0.001 % to about 2%, by weight by volume of the total suspension.
An aqueous suspension may further include one or more pharmaceutically acceptable additives.
The particle size of the present invention is measured using light scattering technique (Malvern Sizer). The fine particle size contributes to homogeneity on prolonged storage,
The average particle size of the gefitinib in the present invention is less than about 50 μπι.
The present invention containing pharmaceutical active agent present at concentrations of 50 mg per mL, 25 mg per mL may be prepared with the above mentioned excipients using different proportions.
An aqueous suspension of the present invention is easily administrable for geriatric patients and thus patient compliance can be achieved.
A pharmaceutical composition of the present invention may be used in the treatment of the human or animal body by therapy.
A process for the preparation of an oral suspension comprising mixing therapeutically effective amount of Gefitinib with vehicle containing preservatives followed by addition of one or more suspending agent dispersed in water, wetting agents, sweetening agents,
buffering agents, anticaking agents, chelating agent, antioxidants, flavoring agent and coloring agents where in the said suspension has a pH from 2.5 to 5.5.
The formulations of the present invention were found to be stable throughout the stability testing storage period.
The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood thatmany-variatiOns-and-mO-di^ rationale" and scope of the invention.
Figure 1 shows the bioavailability study of the formulation of the present invention and tablet dosage form of gefitinib. The details of the process of the invention are provided in the examples given below which is provided by way of illustration only and therefore should not be construed to limit the scope of the invention. The preparation of the present invention that can be administered by the oral route is carried out according to the following process: EXAMPLES
The components illustrated by the examples 1 to 20 are expressed in % by weight based on each composition. In a specific embodiment the present invention provides a process for preparation of a composition, which comprises intimately mixing gefitinib with a vehicle containing
preservatives followed by addition of one or more suspending agent dispersed in water, wetting agents, sweetening agents, buffering agents, anticaking agents, chelating agent, antioxidants, flavoring agent, coloring agents and mixed properly through high speed homogenizer until a homogeneous suspension is obtained or as mentioned under individual examples.
The compositions of Example 1 to 20, contains the
Table 1
Example 1 Example 2 Example 3 Example 4
Components
% (w/v) % (w/v) % (w/v) % (w/v)
Gefitinib 2.50 2.50 2.50 "2.50
Propylene glycol 30.00 30.00 30.00 30.00
Sorbitol solution (70% w/v) 20.00 20.00 20.00 20.00
Magnesium aluminium silicate 1.50 1.50 1.50 1.50
Benzyl alcohol 1.00 1.00 1.00 1.00
Polysorbate 80 0.50 0.50 0.50 0.50
Citric acid monohydrate 0.20 0.20 0.20 0.20
Sodium citrate dihydrate 0.30 0.30 0.30 0.30
Colloidal silicon dioxide 0.20 0.20 0.20 0.20
Sodium metabisulfite 0.00 0.10 0.00 0.00
Propyl gallate 0.00 0.00 0.10 0.00
Ascorbic acid 0.00 0.00 0.00 0.10
Pine apple flavor 0.50 0.50 0.50 0.50
Purified water (qs to 100% w/v) as needed as needed as needed as needed The processing steps involved in manufacturing an oral suspension given in example 1 to 4 were given below.
1. Suspending agent was dispersed in water under stirring.
2. Preservative was added to vehicle under stirring followed by addition of wetting agent and added to step (1)
3. pH of the suspension was adjusted to a desired value as needed by adding buffering agents and added to step (2).
4. Sweetening agent was added to step (3) under stirring.
5. Anticaking agent was added to step (4) under stirring
6. Pharmaceutical active agent was added to step (5) under stirring.
7. Antioxidant was added to step (6) under stirring.
8. Flavor was added to step (7) under stirring.
9. Finally the volume was adjusted with water.
Table 2
Example 5 Example 6 Example 7 Example 8
Components
% (w/v) % (w/v) % (w/v) % (w/v)
Gefitinib 5.00 5.00 5.00 5.00
Glycerin 10.00 35.00 0.00 0.00
Propylene glycol 0.00 0.00 10.00 10.00
Sucrose 30.00 0.00 10.00 0.00
Sucralose 0.00 0.25 0.00 0.00
Sorbitol solution (70% w/v) 0.00 0.00 0.00 20.00
Saccharin 0.00 0.00 0.25 0.25
Polyvinylpyrrolidone 1.25 1.25 0.00 0.00
Sodium lauryl sulphate 0.50 0.50 0.50 0.50
Methyl paraben 0.18 0.18 0.00 0.00
Propyl paraben 0.02 0.02 0.00 0.00
Methyl paraben sodium 0.00 0.00 0.18 0.18
Propyl paraben sodium 0.00 0.00 0.02 0.02
Citric acid monohydrate 0.20 0.20 0.00 0.00
Sodium citrate dihydrate 0.30 0.30 0.00 0.00
Colloidal silicon dioxide 1.00 1.00 0.00 0.00
Hypromellose 2.00 1.50 0.25 0.25
Lemon flavor 0.20 0.25 0.00 0.25
Purified water (qs to 100% w/v) as needed as needed as needed as needed
The formulations given in examples 5 to 8 were prepared using similar procedure described in example 1 to 4. Preservatives like methyl paraben and propyl paraben were heated in glycerol in example 5 and 6.
Table 3
Example 9 Example 10 Example 1 1 Example 12
Components
% (w/v) % (w/v) % (w/v) % (w/v)
Gefitinib 5.00 2.50 2.50 2.50
Glycerin 35.00 0.00 0.00 0.00
Propylene glycol 0.00 30.00 30.00 30.00
Sucralose 0.25 0.00 0.00 0.00
Sorbitol solution (70% w/v) 0.00 . 20.00 20.00 20.00
Hypromellose 0.75 0.00 0.00 0.00
Carbomer 0.00 0.50 0,00 0,00
Magnesium aluminium silicate 0.00 0.00 1.00 0.00
Xanthan gum 0.00 0.00 0.00 0.25
Benzyl alcohol 0.00 1.00 1.00 1.00
Polysorbate 80 0.00 0.50 0.50 0.25
Polyvinylpyrrolidone 1.25 0.00 0.00 0.00
Sodium lauryl sulfate 0.50 0.00 0.00 0.00
Methyl paraben 0.18 0.00 0.00 0.00
Propyl paraben 0.02 0.00 0.00 0.00
Citric acid monohydrate 0.20 0.20 0.20 0.20
Sodium citrate dihydrate 0.30 0.10 0.10 0.10
Colloidal silicon dioxide 1.00 0.20 0.20 0.20
Lemon flavor 0.10 0.50 0.50 0.50
Purified water (qs to 100% w/v) as needed as needed as needed as needed
The formulations given in examples 9 to 12 were prepared using similar procedure described in example 1 to 4.
Table 4
Example 13 Example 14 Example 15 Example 16
Components
% (w/v) % (w/v) % (w/v) % (w/v)
Gefitinib 2.50 2.50 2.50 2.50
Propylene glycol 30.00 30.00 30.00 30.00
Sorbitol solution (70% w/v) 20.00 20.00 20.00 20.00
Magnesium aluminium silicate 0.00 0.00 LOO 0.00
Xanthan gum 0.20 0.00 0.00 0.20
Benzyl alcohol 0.10 0.10 1.00 1.00
Polysorbate 80 0.50 0.25 0.25 0.25
Poloxamer 0.00 0.00 1.00 0.00
Polyethylene glycol 0.00 0.00 0.00 0.50
Citric acid monohydrate 0.20 0.20 0.20 0.20
Sodium citrate dihydrate 0.10 0.10 0.30 0.30
Colloidal silicon dioxide 0.00 0.10 0.20 0.20
Calcium phosphate tribasic 0.10 0.00 0.00 0.00
Hypromellose 0.00 0.50 0.00 0.00
Sodium metabisulfite 0.00 0.00 0.10 0.10
Orange sweet flavor 0.00 0.00 0.10 0.10
FD&C Yellow No.5 0.00 0.02 0.02 0.02
Purified water (qs to 100% w/v) as needed as needed as needed as needed
The formulations given in examples 13 to 16 were prepared using similar procedure described in example 1 to 4. FD&C Yellow No.5 was used as coloring agent in examples 14, 15 and 16 respectively.
Table 5
Example 17 Example 18 Example 19 Example 20
Components
% (w/v) % (w/v) % (w/v) % (w/v)
Gefitinib 2.50 2.50 2.50 2.50
Propylene glycol 30.00 30.00 30.00 30.00
Sorbitol solution (70% w/v) 20.00 20.00 20.00 20.00
Magnesium aluminium silicate 1.50 1.50 1.50 1.50
Benzyl alcohol 1.00 1.00 1.00 1.00
Polysorbate 80 , 0.50 0.50 0.50 0.50
Citric acid monohydrate 0.20 0.20 0.20 0.20
Sodium citrate dihydrate 0.30 0.30 0.30 0.30
Colloidal silicon dioxide 0.20 0.20 0.20 0.20
Sodium metabisulfite 0.10 0.10 0.10 0.10
Disodium edetate 0.10 0.10 0.10 0.10
Lemon flavor 0.50 0.50 0.50 0.50
D&C Yellow No.10 0.02 0.00 0.00 0.00
FD&C Yellow No.6 0.00 , 0.02 0.00 0.00
FD&C yellow No.5 0.00 0.00 0.02 0.00
Carmoisine 0.00 0.00 0.00 0.02
Purified water (qs to 100% w/v) as needed as needed as needed as needed
The formulations given in examples 17 to 20 were prepared using similar procedure described in example 1 to 4. Disodium edetate was used as chelating agent, D&C Yellow No.10, FD&C Yellow No.6, FD&C yellow No.5 and carmoisine were used as coloring agents in examples 17,18,19 and 20 respectively.
BIOAVAILABILITY STUDY FOR THE COMPOSITIONS IN ACCORDANCE WITH THE INVENTION:
The plasma kinetics of the oral suspension as described in above mentioned examples have been compared with those of the gefitinib tablets in a comparative study. This comparative study was carried out with wistar albino rats; weighing 150-280 grams which were divided into different sets of study (one male and one female in each set) and fasted overnight prior to dosing, but were permitted water ad libitum. Both formulations were administered at the dose of 20 mg/kg body weight. Blood samples were collected by puncturing retero-orbital sinus of the anaesthetized rats (with anesthetic light isoflurane) at different intervals post administration. Blood collection was done in prefilled heparin centrifugation tubes. The blood samples collected were subjected for the subsequent centrifugation and followed by analytical procedure with the use of LCMS technique. The areas under the blood drug concentration versus time curves were calculated by the trapezoidal rule. The analysis was done with respect to AUC (area under curve) and Cmax (maximum concentration).
The average AUC and Cmax values from typical trial runs are shown in the following table.
Table 6
AUC Cmax Tniax
Example No.
(ng*hr/mL) (ng/mL) (min)
Comparative
7928.531 1023.83 240
Example (Tablet)
Example 9 10570.566 1442.36 60
As will be seen from the above table, compositions in accordance with the present invention exhibit adequate bioavailability (AUC and Cmax) in comparison with the commercial tablet dosage form.
The aforementioned table gives an account of the bioavailability (AUC, Cmax) of the Gefitinib tablet dosage form and formulation in the present invention.
ADVANTAGES OF THE INVENTION a) Oral suspension of an aniloquinazoline derivative for example gefitnib is prepared which is used as EGFR tyrosine kinase inhibitor for the monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer or unresectable head and neck cancer.
administered so particularly preferable in geriatric patients.
c) Gefitinib oral suspension can be a viable alternative to patients who find it difficult to swallow solid dosage forms.
d) The advantage also lies in the attainment of adequate therapeutic levels of drug concentration in comparison with the commercial tablet dosage form. e) The advantage further encompasses the stability aspects and the formulation is found to be stable throughout the period of the stability study.
f) Industrial applicability, as ease of manufacturing procedure for the scale-up batches and more economical.
g) Particularly till date, the use of this said composition in an orally administrable suspension is not commercially available.
Claims
1. An oral suspension comprising gefitinib along with one or more pharmaceutically acceptable additives.
2. The oral suspension of claim 1 , wherein the average particle size of the gefitinib is less than about 50 μιη.
3. The oral aqueous suspension of claim 1 , wherein the pharmaceutically acceptable additives comprise one or more of a vehicle, suspending agents, preservatives, wetting agents, sweetening agents, buffering agents, anticaking agents* chelating agent, antioxidants, flavoring agent, coloring agents and the like.
-4-.— Ihe-oral-aqueous-suspension-ac^^
from water, glycerin, propylene glycol or mixtures thereof.
5. The oral aqueous suspension according to claim 3, wherein the suspending agent is selected from hypromellose, polyvinylpyrrolidone, magnesium aluminium silicate, xanthan gum and carbomer or mixtures thereof.
6. The oral aqueous suspension according to claim 3, wherein the preservative is selected from methyl paraben, propyl paraben or salts or benzoic acid or sodium benzoate thereof, either individually or in combination.
7. The oral aqueous suspension according to claim 3, wherein the wetting agent is selected from polyoxyethylene sorbitan esters such as polysorbate 20, 80, sodium lauryl sulphate, poloxamers, polyethylene glycol or mixtures thereof.
8. The oral aqueous suspension according to claim 3, wherein the sweetening agent is selected from sucralose, sorbitol solution and saccharin.
9. The oral aqueous suspension according to claim 3, wherein the buffering agent is selected from citric acid, sodium citrate or mixture thereof to adjust the pH of the suspension from 2.5 to 5.5.
10. The oral aqueous suspension of claim3, wherein the anticaking agent is selected from colloidal silicon dioxide, calcium phosphate tribasic or mixtures thereof.
1 1. The oral aqueous suspension according to claim 3, wherein the antioxidant is selected from sodium metabisulfite, propyl gallate or ascorbic acid.
12. A process for producing an aqueous oral suspension according to any one of preceding claims, which comprises mixing therapeutically effective amount of Gefitinib with vehicle containing preservatives followed by addition of one or more suspending agent dispersed in water, wetting agents, sweetening agents, buffering agents, anticaking agents, chelating agent, antioxidants, flavoring agent and coloring agents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2013/000194 WO2014147631A1 (en) | 2013-03-22 | 2013-03-22 | Formulation comprising gefitinib as oral suspension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2013/000194 WO2014147631A1 (en) | 2013-03-22 | 2013-03-22 | Formulation comprising gefitinib as oral suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014147631A1 true WO2014147631A1 (en) | 2014-09-25 |
Family
ID=48746095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2013/000194 WO2014147631A1 (en) | 2013-03-22 | 2013-03-22 | Formulation comprising gefitinib as oral suspension |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2014147631A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019162756A3 (en) * | 2018-02-20 | 2019-10-31 | Ftf Pharma Private Limited | Liquid pharmaceutical compositions of anticancer drugs |
| CN112566625A (en) * | 2018-08-18 | 2021-03-26 | 夫特弗制药私人有限公司 | Oral dosage chemotherapeutic drug suspensions |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457105A (en) | 1992-01-20 | 1995-10-10 | Zeneca Limited | Quinazoline derivatives useful for treatment of neoplastic disease |
| WO1996033980A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
| WO2005070909A1 (en) | 2004-01-22 | 2005-08-04 | Natco Pharma Limited | An improved process for the preparation of gefitinib |
| WO2006090413A1 (en) | 2005-02-23 | 2006-08-31 | Natco Pharma Limited | Novel crystalline form of gefitinib and a process for its preparation |
| US20070270505A1 (en) | 2004-01-23 | 2007-11-22 | The Regents Of The University Of Colorado | Gefitinib Sensitivity-Related Gene Expression and Products and Methods Related Thereto |
| US20090098138A1 (en) | 2006-04-18 | 2009-04-16 | Wellstat Biologics Corporation | Detection of proteins from circulating neoplastic cells |
| US20090186892A1 (en) | 2006-02-10 | 2009-07-23 | Oncotherapy Science, Inc | Methods for treating lung cancers |
| US20090185999A1 (en) | 2008-01-22 | 2009-07-23 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
| US20100137586A1 (en) | 2007-04-16 | 2010-06-03 | Cipla Limited | Process for the Preparation of Gefitinib |
| US20100173285A1 (en) | 2005-02-11 | 2010-07-08 | Memorial Sloan-Kettering Cancer Center | Methods and Compositions for Detecting a Drug Resistant Egfr Mutant |
| WO2010076810A2 (en) | 2008-12-30 | 2010-07-08 | Ind-Swift Laboratories Limited | A process for the preparation of gefitinib |
| US20100184801A1 (en) * | 2009-01-16 | 2010-07-22 | Xiong Cai | Fused amino pyridines for the treatment of brain tumors |
| US20110294686A1 (en) | 2008-09-11 | 2011-12-01 | Drabkin Harry A | Egfr inhibitor therapy responsiveness |
| US20120064090A1 (en) | 2009-03-27 | 2012-03-15 | Kringle Pharma Inc. | Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug |
| WO2012151541A1 (en) * | 2011-05-05 | 2012-11-08 | Novartis Ag | Csf-1r inhibitors for treatment of brain tumors |
| WO2012151523A1 (en) * | 2011-05-05 | 2012-11-08 | Novartis Ag | Csf-1r inhibitors for treatment of brain tumors |
-
2013
- 2013-03-22 WO PCT/IN2013/000194 patent/WO2014147631A1/en active Application Filing
Patent Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457105A (en) | 1992-01-20 | 1995-10-10 | Zeneca Limited | Quinazoline derivatives useful for treatment of neoplastic disease |
| US5616582A (en) | 1992-01-20 | 1997-04-01 | Zeneca Limited | Quinazoline derivatives as anti-proliferative agents |
| WO1996033980A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
| US5770599A (en) | 1995-04-27 | 1998-06-23 | Zeneca Limited | Quinazoline derivatives |
| EP0823900B1 (en) | 1995-04-27 | 2000-12-27 | AstraZeneca AB | Quinazoline derivatives |
| WO2005070909A1 (en) | 2004-01-22 | 2005-08-04 | Natco Pharma Limited | An improved process for the preparation of gefitinib |
| US8017321B2 (en) | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| US20070270505A1 (en) | 2004-01-23 | 2007-11-22 | The Regents Of The University Of Colorado | Gefitinib Sensitivity-Related Gene Expression and Products and Methods Related Thereto |
| US20100173285A1 (en) | 2005-02-11 | 2010-07-08 | Memorial Sloan-Kettering Cancer Center | Methods and Compositions for Detecting a Drug Resistant Egfr Mutant |
| WO2006090413A1 (en) | 2005-02-23 | 2006-08-31 | Natco Pharma Limited | Novel crystalline form of gefitinib and a process for its preparation |
| US20090186892A1 (en) | 2006-02-10 | 2009-07-23 | Oncotherapy Science, Inc | Methods for treating lung cancers |
| US20090098138A1 (en) | 2006-04-18 | 2009-04-16 | Wellstat Biologics Corporation | Detection of proteins from circulating neoplastic cells |
| US20100137586A1 (en) | 2007-04-16 | 2010-06-03 | Cipla Limited | Process for the Preparation of Gefitinib |
| US20090185999A1 (en) | 2008-01-22 | 2009-07-23 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
| US20110294686A1 (en) | 2008-09-11 | 2011-12-01 | Drabkin Harry A | Egfr inhibitor therapy responsiveness |
| WO2010076810A2 (en) | 2008-12-30 | 2010-07-08 | Ind-Swift Laboratories Limited | A process for the preparation of gefitinib |
| US20100184801A1 (en) * | 2009-01-16 | 2010-07-22 | Xiong Cai | Fused amino pyridines for the treatment of brain tumors |
| US20120064090A1 (en) | 2009-03-27 | 2012-03-15 | Kringle Pharma Inc. | Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug |
| WO2012151541A1 (en) * | 2011-05-05 | 2012-11-08 | Novartis Ag | Csf-1r inhibitors for treatment of brain tumors |
| WO2012151523A1 (en) * | 2011-05-05 | 2012-11-08 | Novartis Ag | Csf-1r inhibitors for treatment of brain tumors |
Non-Patent Citations (1)
| Title |
|---|
| CANTARINI M V ET AL: "Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 26, no. 10, 1 October 2004 (2004-10-01), pages 1630 - 1636, XP004682052, ISSN: 0149-2918, DOI: 10.1016/J.CLINTHERA.2004.10.011 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019162756A3 (en) * | 2018-02-20 | 2019-10-31 | Ftf Pharma Private Limited | Liquid pharmaceutical compositions of anticancer drugs |
| CN112566625A (en) * | 2018-08-18 | 2021-03-26 | 夫特弗制药私人有限公司 | Oral dosage chemotherapeutic drug suspensions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9155721B2 (en) | Delayed release, oral dosage compositions that contain amorphous CDDO-Me | |
| AU2003220058B2 (en) | Palatable oral suspension and method | |
| US20080274196A1 (en) | Oral Pharmaceutical Suspension Compositions Of Fexofenadine | |
| US20230338287A1 (en) | Amlodipine formulations | |
| AU2016372683A1 (en) | Complexes of celecoxib and its salts and derivatives process for the preparation thereof and pharmaceutical compositions containing them | |
| EP3013323A2 (en) | Complex granule formulation having improved stability comprising levocetirizine and montelukast | |
| WO2014147631A1 (en) | Formulation comprising gefitinib as oral suspension | |
| WO2014041551A1 (en) | Formulation comprising imatinib as oral solution | |
| US20200078303A1 (en) | Pharmaceutical formulations of suvorexant | |
| US11890273B2 (en) | Losartan liquid formulations and methods of use | |
| US20100272800A1 (en) | Orally disintegrating olanzapine tablet | |
| US11865099B2 (en) | Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof | |
| WO2013109230A1 (en) | Pharmaceutical compositions comprising tadalafil | |
| EP3968955A1 (en) | Pharmaceutical oral liquid solution of ivacaftor | |
| WO2022185338A1 (en) | Stable oral suspension of celecoxib and method of preparation thereof | |
| WO2013062497A1 (en) | Liquid pharmaceutical formulations | |
| WO2013095314A1 (en) | Pharmaceutical formulations comprising risperidone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13733464 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 13733464 Country of ref document: EP Kind code of ref document: A1 |